Article(id=1325224472692798207, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224446230934140, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2026.02.006, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1758988800000, receivedDateStr=2025-09-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793887735769, onlineDateStr=2026-11-05, pubDate=1770652800000, pubDateStr=2026-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793887735769, onlineIssueDateStr=2026-11-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793887735769, creator=13701087609, updateTime=1793887735769, updator=13701087609, issue=Issue{id=1325224446230934140, tenantId=1146029695717560320, journalId=1319690329412173987, year='2026', volume='47', issue='2', pageStart='107', pageEnd='212', issueExtLink='null', onlineDate='null', pubDate='1770652800000', pubDateStr='2026-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793887729460, creator='13701087609', updateTime=1793934840172, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325422043109400703, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224446230934140, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325422043109400704, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325224446230934140, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=149, endPage=156, ext={EN=ArticleExt(id=1325224473099645696, articleId=1325224472692798207, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To investigate the impact of osimertinib targeted therapy on short-term efficacy in patients with epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).

Methods

A retrospective analysis was conducted on clinical data from 134 patients with EGFR-mutated advanced NSCLC admitted to our hospital from December 2023 to March 2025. Patients were divided into a control group(pemetrexed+cisplatin chemotherapy, n=64) and a combination group(osimertinib+pemetrexed+cisplatin chemotherapy, n=70) according to the actual treatment received. The short-term efficacy, serum tumor markers [carcinoembryonic antigen(CEA), cytokeratin 19 fragment antige(Cyfra) 21-1, neuron-specific enolase(NSE)], angiogenesis indicators[vascular endothelial growth factor(VEGF), matrix metalloproteinase(MMP)-9, cytosolic thymidine kinase(TK)1], and adverse reactions were compared between the two groups. Based on the Kaplan-Meier survival curve, the overall survival(OS) and progression-free survival(PFS) were compared.

Results

After treatment, the disease control rate(DCR) in the combination group was higher than that in the control group(90.00% vs. 75.00%, P<0.05). Serum levels of CEA, Cyfra21-1, NSE, VEGF, MMP-9, and TK1 in the combination group were significantly lower than those in the control group(P<0.05). There was no statistically significant difference in adverse reactions between the two groups(P>0.05). The survival functions of OS and PFS in the combination group were better than those in the control group(χ2=4.720, 5.014, P=0.030, 0.025).

Conclusion

Osimertinib targeted therapy for patients with advanced NSCLC with EGFR mutations can significantly reduce serum tumor markers and angiogenesis indicators, improves DCR, OS rate, and prolong the median PFS period, and does not significantly increase the adverse reactions.

, authors=Lei NIU, Chengyu HUO, Zongzhi LIU, authorsList=Lei NIU, Chengyu HUO, Zongzhi LIU, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1325224473305166593, articleId=1325224472692798207, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=奥希替尼靶向治疗对EGFR突变晚期非小细胞肺癌患者血清肿瘤标志物及预后的影响, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

探究奥希替尼靶向治疗对表皮生长因子受体(epidermal growth factor receptor,EGFR)突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者近期疗效指标等的影响。

方法

回顾性分析2023年12月至2025年3月我院收治的134例EGFR突变晚期NSCLC患者的临床资料,根据实际治疗方案分为对照组(培美曲塞+顺铂化疗,n=64)和联合组(奥希替尼+培美曲塞+顺铂化疗,n=70)。分析并比较两组近期疗效、血清肿瘤标志物[癌胚抗原(carcinoembryonic antigen,CEA)、细胞角蛋白19片段(cytokeratin 19 fragment antigen,Cyfra)21-1、神经元特异性烯醇化酶(neuron-specific enolase,NSE)]、血管新生指标[血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶(matrix metalloproteinase,MMP)-9、细胞质胸苷激酶(thymidine kinase,TK)1]及不良反应情况。基于Kaplan-Meier生存曲线,对比两组总生存期(overall survival,OS)及无进展生存(progression free survival,PFS)情况。

结果

治疗后,联合组疾病控制率(disease control rate,DCR)高于对照组(90.00% vs. 75.00%,P<0.05);联合组血清CEA、Cyfra21-1、NSE、VEGF、MMP-9及TK1水平均显著低于对照组(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。联合组OS、PFS生存函数均优于对照组(χ2=4.720、5.014,P=0.030、0.025)。

结论

奥希替尼靶向治疗能明显降低EFGR突变晚期NSCLC患者血清肿瘤标志物及血管新生指标水平,提高DCR、OS率,延长中位PFS期,且未明显增加不良反应。

, authors=牛磊, 霍承瑜, 刘宗志, authorsList=牛磊, 霍承瑜, 刘宗志, authorCompany=null, correspAuthors=null, authorNote=

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=mxnMbmQbotRkTc44F1qtew==, magXml=lisnbgCU9MpzRqoWZ2xxSA==, pdfUrl=null, pdf=bjqThqH/MNTz7urkij4iIA==, pdfFileSize=1017144, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=H6rUkNMulQ0wq/D6+W4iqw==, mapNumber=null, fund=null)}, authors=[Author(id=1325224473619739398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224473707819784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224473619739398, language=EN, stringName=Lei NIU, firstName=Lei, middleName=null, lastName=NIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475385541385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224473619739398, language=CN, stringName=牛磊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio={"content":"

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

"}, bioImg=null, bioContent=

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])]), Author(id=1325224475461038859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224475532342029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475461038859, language=EN, stringName=Chengyu HUO, firstName=Chengyu, middleName=null, lastName=HUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475595256590, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475461038859, language=CN, stringName=霍承瑜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])]), Author(id=1325224475666559760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224475746251538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475666559760, language=EN, stringName=Zongzhi LIU, firstName=Zongzhi, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475813360403, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475666559760, language=CN, stringName=刘宗志, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])])], keywords=[Keyword(id=1325224475888857876, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=1, keyword=non-small cell lung cancer), Keyword(id=1325224475955966741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=2, keyword=epidermal growth factor receptor), Keyword(id=1325224476023075606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=3, keyword=osimertinib), Keyword(id=1325224476090184471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=4, keyword=pemetrexed), Keyword(id=1325224476157293336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=5, keyword=cisplatin), Keyword(id=1325224476232790809, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=EN, orderNo=6, keyword=prognosis), Keyword(id=1325224476295705370, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=1, keyword=非小细胞肺癌), Keyword(id=1325224476371202843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=2, keyword=表皮生长因子受体), Keyword(id=1325224476442506012, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=3, keyword=奥希替尼), Keyword(id=1325224476513809181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=4, keyword=培美曲塞), Keyword(id=1325224476585112350, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=5, keyword=顺铂), Keyword(id=1325224476673192735, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, language=CN, orderNo=6, keyword=预后)], refs=[Reference(id=1325224476773856032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG Y, VACCARELLA S, MORGAN E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study[J]. Lancet Oncol, 2023,24(11): 1206-1218., articleTitle=null, refAbstract=null), Reference(id=1325224476845159202, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=BRAZEL D, KROENING G, NAGASAKA M. Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: diagnosis and treatment options[J]. Bio Drugs, 2022, 36(6): 717-729., articleTitle=null, refAbstract=null), Reference(id=1325224476920656675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=MOK T, NAKAGAWA K, PARK K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722[J]. J Clin Oncol, 2024, 42(11): 1252-1264., articleTitle=null, refAbstract=null), Reference(id=1325224476991959844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=GRAZINI U, MARKOVETS A, IRELAND L, et al.Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA/PTEN alterations[J]. Clin Cancer Res, 2024, 30(18): 4143-4154., articleTitle=null, refAbstract=null), Reference(id=1325224477080040229, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=HERBST RS, WU YL, JOHN T, et al. Adjuvant osimertinib for resected EGFR-mutated stage ⅠB-ⅢA non-small-cell lung cancer: updated results from the phase Ⅲ randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840., articleTitle=null, refAbstract=null), Reference(id=1325224477147149094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: non-small cell lung cancer(Version 1.2024)[EB/OL]. (2024-07-10)[2025-08-12]. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf., articleTitle=null, refAbstract=null), Reference(id=1325224477218452263, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=HENDRIKS LE, KERR KM, MENIS J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(4): 339-357., articleTitle=null, refAbstract=null), Reference(id=1325224477277172520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. CSCO非小细胞肺癌诊疗指南2025[M]. 北京: 人民卫生出版社, 2025: 48-55., articleTitle=null, refAbstract=null), Reference(id=1325224477344281385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ARAKI T, KANDA S, HORINOUCHI H, et al. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance[J]. Jpn J Clin Oncol, 2023, 53(7): 547-561., articleTitle=null, refAbstract=null), Reference(id=1325224477411390250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志, 2020, 42(4): 257-287., articleTitle=null, refAbstract=null), Reference(id=1325224477495276331, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHWARTZ LH, SEYMOUR L, LITIERE S, et al. RECIST 1.1‐standardisation and disease-specific adaptations:perspectives from the RECIST Working Group[J]. Eur J Cancer, 2016, 62(7): 138-145., articleTitle=null, refAbstract=null), Reference(id=1325224477566579500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=KLUETZ PG, CHINGOS DT, BASCH EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events(PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016, 35(1): 67-73., articleTitle=null, refAbstract=null), Reference(id=1325224477646271277, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=PU J, GUO H, YU R, et al. Pan-cancer molecular analysis of EGFR large fragment deletion in the Asian population[J]. Cancer Med, 2023, 12(7): 8083-8088., articleTitle=null, refAbstract=null), Reference(id=1325224477709185838, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=OXNARD GR, CHEN R, PHARR JC, et al. Germline EGFR mutations and familial lung cancer[J]. J Clin Oncol, 2023,41(34): 5274-5284., articleTitle=null, refAbstract=null), Reference(id=1325224477793071919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=PATEL SA, WEISS J. Advances in the treatment of non-small cell lung cancer: immunotherapy[J]. Clin Chest Med, 2020,41(2): 237-247., articleTitle=null, refAbstract=null), Reference(id=1325224477864375088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=QURESHI S, BOILY G, BOULANGER J, et al. Advanced lung cancer patients' use of EGFR tyrosine kinase inhibitors and overall survival: real-world evidence from Quebec, Canada[J]. Curr Oncol, 2022, 29(11): 8043-8073., articleTitle=null, refAbstract=null), Reference(id=1325224477931483953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=WU YL, ZHOU Q. Combination therapy for EGFR-mutated lung cancer[J]. N Engl J Med, 2023, 389(21): 2005-2007., articleTitle=null, refAbstract=null), Reference(id=1325224478006981426, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=JANNE PA, PLANCHARD D, KOBAYASHI K, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2024, 42(7): 808-820., articleTitle=null, refAbstract=null), Reference(id=1325224478086673203, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=PATIL T, GAO D, WATSON A, et al. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations[J]. Lung Cancer, 2025, 199(1): 108040., articleTitle=null, refAbstract=null), Reference(id=1325224478149587764, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG X, LI Z, WANG L, et al. Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation:results from a multicenter phase Ⅱ study with ctDNA analysis[J]. Bio Med Central Med, 2025, 23(1): 223., articleTitle=null, refAbstract=null), Reference(id=1325224479835697973, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=麻发强, 陆方阳, 赵莉莉, 等. 奥希替尼联合培美曲塞加卡铂治疗晚期非鳞状非小细胞肺癌的疗效[J]. 西部医学, 2022, 34(11): 1679-1682., articleTitle=null, refAbstract=null), Reference(id=1325224479911195446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=杜敏娟, 徐晓光. 奥西替尼靶向治疗对晚期非小细胞肺癌患者的疗效[J]. 中国老年学杂志, 2021, 41(11): 2286-2289., articleTitle=null, refAbstract=null), Reference(id=1325224479982498615, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=CHOI SH, YOO SS, LEE SY, et al. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer[J]. Arch Pharm Res, 2022, 45(4):263-279., articleTitle=null, refAbstract=null), Reference(id=1325224480066384696, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=HWANG KE, KIM HJ, SONG IS, et al. Salinomycin suppresses TGF-β-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer[J]. Int J Med Sci, 2021, 18(3): 715-726., articleTitle=null, refAbstract=null), Reference(id=1325224480150270777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=PLANCHARD D, JANNE PA, CHENG Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21): 1935-1948., articleTitle=null, refAbstract=null), Reference(id=1325224480242545466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=浦柳美, 黄国兰, 潘天宇, 等. 甲磺酸奥希替尼治疗晚期非小细胞肺癌的效果及预后相关因素分析[J]. 中南医学科学杂志, 2023, 51(3): 376-379., articleTitle=null, refAbstract=null), Reference(id=1325224480301265723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=TANAKA K, ASAHINA H, KISHIMOTO J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR(T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial[J]. Eur J Cancer, 2021,149(4): 14-22., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.02.006, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.02.006, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2026.02.006, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2026.02.006, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1770652800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
奥希替尼靶向治疗对EGFR突变晚期非小细胞肺癌患者血清肿瘤标志物及预后的影响
牛磊 , 霍承瑜 , 刘宗志
世界临床药物 | 研究论文 2026,47(2): 149-156
收起
收藏切换
世界临床药物 |研究论文 2026 , 47 (2) : 149 -156
奥希替尼靶向治疗对EGFR突变晚期非小细胞肺癌患者血清肿瘤标志物及预后的影响
全屏
[Author(id=1325224473619739398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224473707819784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224473619739398, language=EN, stringName=Lei NIU, firstName=Lei, middleName=null, lastName=NIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475385541385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224473619739398, language=CN, stringName=牛磊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio={"content":"

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

"}, bioImg=null, bioContent=

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])]), Author(id=1325224475461038859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224475532342029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475461038859, language=EN, stringName=Chengyu HUO, firstName=Chengyu, middleName=null, lastName=HUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475595256590, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475461038859, language=CN, stringName=霍承瑜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])]), Author(id=1325224475666559760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325224475746251538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475666559760, language=EN, stringName=Zongzhi LIU, firstName=Zongzhi, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325224475813360403, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, authorId=1325224475666559760, language=CN, stringName=刘宗志, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=民航总医院胸外科,北京 100123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325224473535853314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, xref=null, ext=[AuthorCompanyExt(id=1325224473544241923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China), AuthorCompanyExt(id=1325224473552630532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325224472692798207, companyId=1325224473535853314, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=民航总医院胸外科,北京 100123)])])]
牛磊, 霍承瑜, 刘宗志
作者信息
  • 民航总医院胸外科,北京 100123
作者简介:

牛磊,副主任医师,研究方向:肺癌、食管癌及胸外科疾病诊治。

Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer
Lei NIU, Chengyu HUO, Zongzhi LIU
Affiliations
  • Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China
出版时间: 2026-02-10 doi: 10.13683/j.wph.2026.02.006
文章导航
收藏切换
目的

探究奥希替尼靶向治疗对表皮生长因子受体(epidermal growth factor receptor,EGFR)突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者近期疗效指标等的影响。

方法

回顾性分析2023年12月至2025年3月我院收治的134例EGFR突变晚期NSCLC患者的临床资料,根据实际治疗方案分为对照组(培美曲塞+顺铂化疗,n=64)和联合组(奥希替尼+培美曲塞+顺铂化疗,n=70)。分析并比较两组近期疗效、血清肿瘤标志物[癌胚抗原(carcinoembryonic antigen,CEA)、细胞角蛋白19片段(cytokeratin 19 fragment antigen,Cyfra)21-1、神经元特异性烯醇化酶(neuron-specific enolase,NSE)]、血管新生指标[血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶(matrix metalloproteinase,MMP)-9、细胞质胸苷激酶(thymidine kinase,TK)1]及不良反应情况。基于Kaplan-Meier生存曲线,对比两组总生存期(overall survival,OS)及无进展生存(progression free survival,PFS)情况。

结果

治疗后,联合组疾病控制率(disease control rate,DCR)高于对照组(90.00% vs. 75.00%,P<0.05);联合组血清CEA、Cyfra21-1、NSE、VEGF、MMP-9及TK1水平均显著低于对照组(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。联合组OS、PFS生存函数均优于对照组(χ2=4.720、5.014,P=0.030、0.025)。

结论

奥希替尼靶向治疗能明显降低EFGR突变晚期NSCLC患者血清肿瘤标志物及血管新生指标水平,提高DCR、OS率,延长中位PFS期,且未明显增加不良反应。

非小细胞肺癌  /  表皮生长因子受体  /  奥希替尼  /  培美曲塞  /  顺铂  /  预后
Objective

To investigate the impact of osimertinib targeted therapy on short-term efficacy in patients with epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).

Methods

A retrospective analysis was conducted on clinical data from 134 patients with EGFR-mutated advanced NSCLC admitted to our hospital from December 2023 to March 2025. Patients were divided into a control group(pemetrexed+cisplatin chemotherapy, n=64) and a combination group(osimertinib+pemetrexed+cisplatin chemotherapy, n=70) according to the actual treatment received. The short-term efficacy, serum tumor markers [carcinoembryonic antigen(CEA), cytokeratin 19 fragment antige(Cyfra) 21-1, neuron-specific enolase(NSE)], angiogenesis indicators[vascular endothelial growth factor(VEGF), matrix metalloproteinase(MMP)-9, cytosolic thymidine kinase(TK)1], and adverse reactions were compared between the two groups. Based on the Kaplan-Meier survival curve, the overall survival(OS) and progression-free survival(PFS) were compared.

Results

After treatment, the disease control rate(DCR) in the combination group was higher than that in the control group(90.00% vs. 75.00%, P<0.05). Serum levels of CEA, Cyfra21-1, NSE, VEGF, MMP-9, and TK1 in the combination group were significantly lower than those in the control group(P<0.05). There was no statistically significant difference in adverse reactions between the two groups(P>0.05). The survival functions of OS and PFS in the combination group were better than those in the control group(χ2=4.720, 5.014, P=0.030, 0.025).

Conclusion

Osimertinib targeted therapy for patients with advanced NSCLC with EGFR mutations can significantly reduce serum tumor markers and angiogenesis indicators, improves DCR, OS rate, and prolong the median PFS period, and does not significantly increase the adverse reactions.

non-small cell lung cancer  /  epidermal growth factor receptor  /  osimertinib  /  pemetrexed  /  cisplatin  /  prognosis
牛磊, 霍承瑜, 刘宗志. 奥希替尼靶向治疗对EGFR突变晚期非小细胞肺癌患者血清肿瘤标志物及预后的影响. 世界临床药物, 2026 , 47 (2) : 149 -156 . DOI: 10.13683/j.wph.2026.02.006
Lei NIU, Chengyu HUO, Zongzhi LIU. Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer[J]. World Clinical Drug, 2026 , 47 (2) : 149 -156 . DOI: 10.13683/j.wph.2026.02.006

参考文献 引证文献
排序方式:
[1]
ZHANG Y, VACCARELLA S, MORGAN E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study[J]. Lancet Oncol, 2023,24(11): 1206-1218.
[2]
BRAZEL D, KROENING G, NAGASAKA M. Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: diagnosis and treatment options[J]. Bio Drugs, 2022, 36(6): 717-729.
[3]
MOK T, NAKAGAWA K, PARK K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722[J]. J Clin Oncol, 2024, 42(11): 1252-1264.
[4]
GRAZINI U, MARKOVETS A, IRELAND L, et al.Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA/PTEN alterations[J]. Clin Cancer Res, 2024, 30(18): 4143-4154.
[5]
HERBST RS, WU YL, JOHN T, et al. Adjuvant osimertinib for resected EGFR-mutated stage ⅠB-ⅢA non-small-cell lung cancer: updated results from the phase Ⅲ randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840.
[6]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: non-small cell lung cancer(Version 1.2024)[EB/OL]. (2024-07-10)[2025-08-12]. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
[7]
HENDRIKS LE, KERR KM, MENIS J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(4): 339-357.
[8]
中国临床肿瘤学会指南工作委员会. CSCO非小细胞肺癌诊疗指南2025[M]. 北京: 人民卫生出版社, 2025: 48-55.
[9]
ARAKI T, KANDA S, HORINOUCHI H, et al. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance[J]. Jpn J Clin Oncol, 2023, 53(7): 547-561.
[10]
中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志, 2020, 42(4): 257-287.
[11]
SCHWARTZ LH, SEYMOUR L, LITIERE S, et al. RECIST 1.1‐standardisation and disease-specific adaptations:perspectives from the RECIST Working Group[J]. Eur J Cancer, 2016, 62(7): 138-145.
[12]
KLUETZ PG, CHINGOS DT, BASCH EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events(PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016, 35(1): 67-73.
[13]
PU J, GUO H, YU R, et al. Pan-cancer molecular analysis of EGFR large fragment deletion in the Asian population[J]. Cancer Med, 2023, 12(7): 8083-8088.
[14]
OXNARD GR, CHEN R, PHARR JC, et al. Germline EGFR mutations and familial lung cancer[J]. J Clin Oncol, 2023,41(34): 5274-5284.
[15]
PATEL SA, WEISS J. Advances in the treatment of non-small cell lung cancer: immunotherapy[J]. Clin Chest Med, 2020,41(2): 237-247.
[16]
QURESHI S, BOILY G, BOULANGER J, et al. Advanced lung cancer patients' use of EGFR tyrosine kinase inhibitors and overall survival: real-world evidence from Quebec, Canada[J]. Curr Oncol, 2022, 29(11): 8043-8073.
[17]
WU YL, ZHOU Q. Combination therapy for EGFR-mutated lung cancer[J]. N Engl J Med, 2023, 389(21): 2005-2007.
[18]
JANNE PA, PLANCHARD D, KOBAYASHI K, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2024, 42(7): 808-820.
[19]
PATIL T, GAO D, WATSON A, et al. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations[J]. Lung Cancer, 2025, 199(1): 108040.
[20]
WANG X, LI Z, WANG L, et al. Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation:results from a multicenter phase Ⅱ study with ctDNA analysis[J]. Bio Med Central Med, 2025, 23(1): 223.
[21]
麻发强, 陆方阳, 赵莉莉, 等. 奥希替尼联合培美曲塞加卡铂治疗晚期非鳞状非小细胞肺癌的疗效[J]. 西部医学, 2022, 34(11): 1679-1682.
[22]
杜敏娟, 徐晓光. 奥西替尼靶向治疗对晚期非小细胞肺癌患者的疗效[J]. 中国老年学杂志, 2021, 41(11): 2286-2289.
[23]
CHOI SH, YOO SS, LEE SY, et al. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer[J]. Arch Pharm Res, 2022, 45(4):263-279.
[24]
HWANG KE, KIM HJ, SONG IS, et al. Salinomycin suppresses TGF-β-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer[J]. Int J Med Sci, 2021, 18(3): 715-726.
[25]
PLANCHARD D, JANNE PA, CHENG Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21): 1935-1948.
[26]
浦柳美, 黄国兰, 潘天宇, 等. 甲磺酸奥希替尼治疗晚期非小细胞肺癌的效果及预后相关因素分析[J]. 中南医学科学杂志, 2023, 51(3): 376-379.
[27]
TANAKA K, ASAHINA H, KISHIMOTO J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR(T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial[J]. Eur J Cancer, 2021,149(4): 14-22.
2026年第47卷第2期
56
14
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2026.02.006
  • 接收时间:2025-09-28
  • 首发时间:2026-11-05
  • 出版时间:2026-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-09-28
基金
作者信息
    民航总医院胸外科,北京 100123
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.02.006
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏